NEW YORK (AP) -- Shares of Inspire Pharmaceuticals Inc. surged Wednesday away from its 52-week low, the day before the Food and Drug Administration is due to rule on the company’s dry eye treatment. Inspire shares rose $1, or 16.4 percent, to $7.10 in afternoon trading on the Nasdaq at more than seven times their average volume. Shares have fallen from a 52-week high of $18.82 in December to a 52-week low of $6.08 on Tuesday.
